<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04966416</url>
  </required_header>
  <id_info>
    <org_study_id>CALC-001</org_study_id>
    <nct_id>NCT04966416</nct_id>
  </id_info>
  <brief_title>Calcinosis Reduction by Pyrophosphate in SSC</brief_title>
  <official_title>The Effect of Orally Administered Pyrophosphate on Calcinosis Formation in Systematic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Szeged University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Research Centre for Natural Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Debrecen Dept. of Rheumatology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Szeged University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Calcinosis, i.e. crystal-like nodules are troublesome complication of systemic sclerosis, an&#xD;
      autoimmune disease. Pyrophosphate inhibits its formation is laborytory. We would like to test&#xD;
      if orally administered pyrophosphate prevents calcinosis formation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Calcinosis, the formation of hydroxyapatite subcutaneous nodules, often complicates systemic&#xD;
      sclerosis. There is no standard treatment for it. Based upon our preclinical experienc, we&#xD;
      would like to test it orally administered pyrophosphate inhibits calciosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the size of calcinosis nodues.</measure>
    <time_frame>52 weeks+ 16 weeks</time_frame>
    <description>Volumetric assessment with low energy CT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of the severity of sympthoms caused by calcinosis</measure>
    <time_frame>52 weeks+ 16 weeks</time_frame>
    <description>Visual analogue scale (0-100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the activity of calcinosis</measure>
    <time_frame>52 weeks+ 16 weeks</time_frame>
    <description>Visual analogue scale (0-100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the size of calcinosis by ultrasound</measure>
    <time_frame>52 weeks+ 16 weeks</time_frame>
    <description>Volumetric assessment by ultrasound</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Systemic Sclerosis</condition>
  <condition>Scleroderma</condition>
  <arm_group>
    <arm_group_label>Pyrophosphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pyrophosphate</intervention_name>
    <description>50 mg/kg bwt once daily in gelatine capsules.</description>
    <arm_group_label>Pyrophosphate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Glucose in gelatine capsules.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  to meet ACR/ EULAR classification criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  severe upper minfestation of SSC&#xD;
&#xD;
          -  hypo- or hyperthyreoidism&#xD;
&#xD;
          -  QT prolongation on ECG&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>László Kovács, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Szeged University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>András Váradi, PhD, DSc</last_name>
    <role>Study Director</role>
    <affiliation>Department of Enzymology, Research Centre for Natural Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>László Kovács, MD, PhD</last_name>
    <phone>+36309081611</phone>
    <email>kovacs.laszlo@med.u-szeged.hu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Márta Bocskai, MD</last_name>
    <phone>+3662341520</phone>
    <email>bocskai.marta@med.u-szeged.hu</email>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 14, 2021</study_first_submitted>
  <study_first_submitted_qc>July 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2021</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Szeged University</investigator_affiliation>
    <investigator_full_name>László Kovács MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>calcinosis</keyword>
  <keyword>pyrophosphate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Calcinosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

